Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174356 · ClinicalTrials.gov registry record · Phase 1
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT00174356 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 39 participants.
The verdict
NCT00174356, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the overall safety and maximum dose of CI 1033 in combination with paclitaxel and carboplatin in patients with NSCLC.
Interventions
- DRUG CARBOPLATIN
- DRUG PACLITAXEL
- DRUG CI 1033
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174356
The ClinicalTrials.gov registry entry for NCT00174356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CARBOPLATIN is the first listed.
NCT00174356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174356 about?
NCT00174356 is a clinical study titled "PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients". The main purpose of this study is to evaluate the overall safety and maximum dose of CI 1033 in combination with paclitaxel and carboplatin in patients with NSCLC.
What is the current status of trial NCT00174356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2002-12. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00174356?
The interventions under investigation include: CARBOPLATIN (DRUG), PACLITAXEL (DRUG), CI 1033 (DRUG).
Who is sponsoring clinical trial NCT00174356?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.